Literature DB >> 7961782

Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis.

K R Siebenlist1, M W Mosesson.   

Abstract

In the presence of plasma transglutaminase (factor XIIIa) fibrin first undergoes intermolecular covalent cross-linking between its gamma chains to create gamma dimers followed by slower cross-linking among its alpha chains to form alpha polymers. Progressive cross-linking of gamma chain dimers occurs at the slowest rate, resulting in gamma trimers and gamma tetramers ("gamma multimers"). Most studies indicate that cross-linked fibrin clots become resistant to fibrinolysis, but the basis for this event is not clear. In this study, we explored the role of gamma chain multimerization compared with alpha polymerization as causal factors in time-dependent development of resistance to fibrinolysis. Fibrin clots prepared from native (intact) fibrinogen were incubated for up to 120 h at near physiological ionic strength and a factor XIIIa level approximating that in plasma. These clots were lysed by plasmin at rates that were inversely proportional to the level of gamma multimers, which increased progressively with the time of incubation. In contrast, fibrin cross-linked at high ionic strength (a condition under which only gamma dimers and alpha polymers form) or fibrin formed in the absence of factor XIII showed no time-dependent decrease in lysis rates. Fibrin cross-linked for a fixed time period with increasing amounts of factor XIIIa contained gamma multimer levels that were proportional to the factor XIIIa concentration and lysed at rates that were inversely proportional to the gamma multimer level. Furthermore, cross-linked fibrin formed from fibrinogen fraction I-9, which has limited potential for alpha polymerization, showed the same reduction in the lysis rate as native cross-linked fibrin. These findings indicate that development of resistance to fibrinolysis of cross-linked fibrin is not measurably dependent upon gamma dimer or alpha polymer formation but develops solely as a function of gamma multimerization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961782

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

2.  Fibrinogen-γ proteolysis and solubility dynamics during apoptotic mouse liver injury: heparin prevents and treats liver damage.

Authors:  Sujith V W Weerasinghe; David S Moons; Peter J Altshuler; Yatrik M Shah; M Bishr Omary
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 3.  Fibrin-based biomaterials: modulation of macroscopic properties through rational design at the molecular level.

Authors:  Ashley C Brown; Thomas H Barker
Journal:  Acta Biomater       Date:  2013-09-19       Impact factor: 8.947

Review 4.  Fibrinogen, red blood cells, and factor XIII in venous thrombosis.

Authors:  B L Walton; J R Byrnes; A S Wolberg
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

5.  The antifibrinolytic function of factor XIII is exclusively expressed through α₂-antiplasmin cross-linking.

Authors:  Steven R Fraser; Nuala A Booth; Nicola J Mutch
Journal:  Blood       Date:  2011-04-06       Impact factor: 22.113

6.  Cationic PAMAM dendrimers aggressively initiate blood clot formation.

Authors:  Clinton F Jones; Robert A Campbell; Amanda E Brooks; Shoeleh Assemi; Soheyl Tadjiki; Giridhar Thiagarajan; Cheyanne Mulcock; Andrew S Weyrich; Benjamin D Brooks; Hamidreza Ghandehari; David W Grainger
Journal:  ACS Nano       Date:  2012-10-24       Impact factor: 15.881

7.  Multiple ligands of von Willebrand factor-binding protein (vWbp) promote Staphylococcus aureus clot formation in human plasma.

Authors:  Lena Thomer; Olaf Schneewind; Dominique Missiakas
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

8.  Functional factor XIII-A is exposed on the stimulated platelet surface.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Steven R Fraser; Claire S Whyte; Nuala A Booth; Nicola J Mutch
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

9.  A reproducible, high throughput method for fabricating fibrin gels.

Authors:  Kaitlin C Murphy; J Kent Leach
Journal:  BMC Res Notes       Date:  2012-08-08

10.  Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis.

Authors:  N J Mutch; J S Koikkalainen; S R Fraser; K M Duthie; M Griffin; J Mitchell; H G Watson; N A Booth
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.